Atlas Private Wealth Advisors Sells 7,604 Shares of The Clorox Company (NYSE:CLX)

Atlas Private Wealth Advisors trimmed its holdings in The Clorox Company (NYSE:CLX - Free Report) by 47.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,392 shares of the company's stock after selling 7,604 shares during the period. Atlas Private Wealth Advisors' holdings in Clorox were worth $1,236,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Clorox by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 15,507,152 shares of the company's stock valued at $2,518,517,000 after acquiring an additional 124,428 shares in the last quarter. Geode Capital Management LLC raised its stake in Clorox by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 3,098,302 shares of the company's stock valued at $501,925,000 after purchasing an additional 69,969 shares in the last quarter. Stifel Financial Corp grew its stake in Clorox by 0.4% during the fourth quarter. Stifel Financial Corp now owns 2,344,408 shares of the company's stock worth $380,761,000 after buying an additional 9,582 shares in the last quarter. Norges Bank acquired a new position in shares of Clorox in the 4th quarter valued at approximately $259,041,000. Finally, Northern Trust Corp lifted its holdings in shares of Clorox by 18.2% during the 4th quarter. Northern Trust Corp now owns 1,494,265 shares of the company's stock worth $242,684,000 after acquiring an additional 230,173 shares during the period. 78.53% of the stock is currently owned by institutional investors.

Clorox Trading Up 0.5%

NYSE:CLX traded up $0.59 during mid-day trading on Monday, hitting $123.66. 556,895 shares of the company's stock were exchanged, compared to its average volume of 1,358,753. The Clorox Company has a fifty-two week low of $122.84 and a fifty-two week high of $171.37. The company has a current ratio of 0.94, a quick ratio of 0.60 and a debt-to-equity ratio of 20.52. The firm has a market capitalization of $15.24 billion, a P/E ratio of 33.77, a PEG ratio of 2.62 and a beta of 0.54. The company has a 50 day simple moving average of $134.91 and a 200-day simple moving average of $148.22.

Clorox (NYSE:CLX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a net margin of 6.38% and a return on equity of 316.87%. The business had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.74 billion. During the same period in the previous year, the business posted $1.71 EPS. Clorox's revenue was down 8.0% on a year-over-year basis. As a group, research analysts expect that The Clorox Company will post 7.15 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Pierre R. Breber acquired 4,000 shares of the stock in a transaction dated Wednesday, May 7th. The stock was bought at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the transaction, the director now directly owns 4,000 shares of the company's stock, valued at $546,280. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.57% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Barclays lowered their price objective on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating for the company in a research report on Wednesday, May 7th. Evercore ISI set a $140.00 price target on Clorox and gave the stock an "underperform" rating in a report on Tuesday, May 6th. JPMorgan Chase & Co. reduced their price objective on Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 6th. Wells Fargo & Company lowered their target price on Clorox from $145.00 to $142.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Finally, Citigroup reduced their price target on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating on the stock in a research note on Monday, April 14th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $151.23.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.